Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics for up to $202m in cash, marking another addition to ...

Eli Lilly, the maker of the popular GLP-1 injectable Mounjaro, has invested heavily in Houston as a biotechnology hub.

Engage Biologics has developed a novel DNA delivery system, called Tethosome, which it says will speed the development of non-viral genetic medicines at Lilly.

A Y Combinator biotech with a unique way of administering genetic treatments was bought up by Eli Lilly for $202 million.

CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be ...

Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...